enVVeno Medical Corporation (NVNO)

enVVeno Medical Corp. has experienced significant stock fluctuations in the past six months. In August 2025, the company received a "not-approvable letter" from the FDA for its VenoValve, causing a substantial stock decline. In September 2025, enVVeno announced it would file a request for supervisory appeal of the FDA's decision. October 2025 saw the company report net losses of $4.5 million and a cash burn of $4.2 million for the third quarter. In November 2025, the FDA upheld its decision, leading to another stock plummet and a shift in focus to enVVe. December 2025 saw shareholders approve a reverse stock split, which was completed in January 2026. In February 2026, enVVeno Medical regained compliance with Nasdaq's minimum bid price requirement. Overall, the stock has experienced a significant downtrend.

Specific information on demand seasonality for enVVeno Medical Corp.'s products is not available. However, the broader market for varicose vein and chronic venous disease treatments is driven by factors such as the high prevalence of these conditions, technological advancements, a preference for minimally invasive procedures, and an increasing geriatric population. Significant seasonality in demand is generally unlikely due to the ongoing nature of these medical conditions.

enVVeno Medical Corp. is a clinical-stage medical device company focused on developing bioprosthetic solutions for venous disease, operating in the Health Technology sector. Their primary product candidates are the VenoValve, a surgical replacement venous valve, and enVVe, a non-surgical, transcatheter-based replacement venous valve system, both designed to treat severe deep venous Chronic Venous Insufficiency (CVI).

enVVeno Medical Corp. operates solely in the United States, concentrating on medical device development.

enVVeno Medical Corp.'s brand reputation has been challenged by regulatory setbacks, including the FDA's "not-approvable letter" for VenoValve and the unfavorable appeal decision, impacting public and investor confidence. Despite these hurdles, some analysts maintain a "Buy" rating, indicating potential long-term growth, but the company faces reputational strain within the medical community and among potential investors.

enVVeno Medical Corporation has 46 institutional owners and shareholders, holding a total of 5,599,264 shares. Major institutional shareholders include Perceptive Advisors Llc, Kingdon Capital Management, L.l.c., CM Management, LLC, Vanguard Group Inc., and Geode Capital Management, Llc. Institutional ownership stands at 29.42% to 34.71% of the stock, while insiders hold 3.57%.